Objective: Epstein-Barr virus (EBV)-positive lymphomas in HIV carriers are paralleled by elevated EBV-DNA loads in the circulation. Approximately 20% of asymptomatic HIV carriers also show elevated circulating EBV-DNA loads. We aimed to characterize the nature of this EBV DNA and to determine the transcriptional phenotype of EBV in blood, in relation to serological parameters.
Design: A total of 197 random asymptomatic HIV carriers, representing 2% of the Dutch HIV-positive population, were sampled for blood, peripheral blood mononuclear cells and plasma. In addition, 39 EBV-DNA carriers were sampled twice, with a 5-year interval.
Methods: EBV-DNA loads were determined by LightCycler-based real-time polymerase chain reaction (PCR). EBV transcription was studied by nucleic acid sequence-based amplification and reverse transcriptase PCR. IgA and IgG antibodies to EBV antigens EBNA1 and VCA-p18 were quantified by synthetic peptide-based enzyme-linked immunosorbent assay.
Results: : Elevated EBV-DNA loads were found in whole blood of 19.3% of the tested HIV population, which were persistent in 82%. Plasma samples were EBV-DNA negative and circulating EBV DNA could be attributed to the B-cell compartment. Transcription of only LMP2 and (non-translated) transcripts from the BamHI-A region of the EBV genome was found, whereas EBNA1, LMP1 and lytic EBV transcripts were absent despite high cellular EBV-DNA loads. IgA-reactivity to VCA-p18 was seen in 69%. IgG to VCA-p18 was significantly higher in high EBV-DNA load carriers.
Conclusion: Asymptomatic HIV carriers show aberrant EBV persistence in the circulation, characterized by elevated, B-cell-associated EBV-DNA loads. EBV transcription is restricted, arguing for EBV gene shutdown in circulating EBV-carrying B cells. Increased IgA and IgG reactive to VCA-p18 is indicative of increased lytic EBV replication, possibly occurring at mucosal lymphoid sites but not in the circulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAD.0b013e3282eeeba0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hodgkin lymphoma: the role of EBV plasma viral load testing in an HIV-endemic setting.
Clin Exp Med
November 2024
Department of Pathology, Division of Virology, Groote Schuur Hospital, University of Cape Town and National Health Laboratory Service, Cape Town, South Africa.
South Africa has a high burden of human immune deficiency virus (HIV)-associated Hodgkin lymphoma (HL) which is typically Epstein-Barr virus (EBV) infected, detected by histological stains. Circulating plasma EBV derived from apoptotic EBV infected tumour cells is a potential biomarker. This study aimed to evaluate the role of plasma EBV load testing in newly diagnosed HL patients and correlate pretreatment plasma EBV levels, HIV status and EBV tumour status with overall survival (OS).
View Article and Find Full Text PDFIncreased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation.
J Hematol Oncol
October 2024
National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China.
Article Synopsis
- Letermovir (LTV) prophylaxis significantly reduces the incidence of clinically significant cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- A study of 230 patients показал that those receiving LTV experienced a higher rate of Epstein-Barr virus (EBV) reactivation (27%) compared to those who did not receive LTV (13%).
- Despite the increased EBV reactivation, there were no major differences in recovery metrics, overall survival, or other complications between the LTV and control groups, suggesting a possible link between LTV use and increased EBV reactivation post-transplant.
Comparison of Epstein-Barr virus copy number in white blood cells of chronic lymphocytic leukemia patients with laboratory prognostic biomarker.
BMC Res Notes
October 2024
Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, P.O. Box: 71345-1735, Shiraz, Iran.
Article Synopsis
- The study investigates the role of Epstein-Barr Virus (EBV) DNA load in the prognosis of Chronic Lymphocytic Leukemia (CLL) patients, comparing it to standard laboratory factors.
- In a sample of 40 untreated CLL patients, EBV-DNA was detected in over half, showing significant differences in key blood parameters such as lactate dehydrogenase (LDH) and platelet counts between EBV positive and negative individuals.
- The findings suggest that measuring EBV-DNA load can help predict disease severity and potentially improve patient management in CLL cases.
[Effect of Plasma Epstein-Barr Virus Nucleic Acid Loads on the Clinical Features and Prognosis in Adult Secondary Hemophagocytic Lymphohistiocytosis].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
August 2024
Department of Geriatric Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu Province, China.
Objective: To investigate the effect of pre-treatment plasma Epstein-Barr virus (EBV) DNA copy number on the clinical features and prognosis of patients with adult secondary hemophagocytic lymphohistiocytosis(sHLH).
Methods: The clinical characteristics, survival rate, and prognostic factors of 171 patients with adult sHLH treated at Jiangsu Province Hospital from June 2017 to January 2022 were retrospectively analyzed in this study. Patients were divided into three groups, including the EBV DNA-negative group(<5.
Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: yes or no?
Blood
November 2024
Department of General Practice, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- Hemophagocytic lymphohistiocytosis (HLH) is a serious immune system disorder, with the most common form in adults being Epstein-Barr virus (EBV)-associated HLH (EBV-HLH), which can lead to severe outcomes depending on the type of immune cells affected.
- In a study of 356 adult patients with EBV-HLH, those who underwent allogeneic hematopoietic stem cell transplantation (HSCT) had a significantly better 5-year survival rate (48.7%) compared to those who did not receive transplantation (16.2%).
- Factors like EBV-DNA levels, remission status, and the presence of graft-versus-host disease influenced survival
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!